A phase II study of carboplatin and amurubicin with a biweekly schedule in patients with advanced squamous cell lung cancer

A phase II study of carboplatin and amurubicin with a biweekly schedule in patients with advanced squamous cell lung cancer - A phase II study of carboplatin and amurubicin with a biweekly schedule in patients with advanced squamous cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007102

Enrollment

Registered

2012-01-19

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer,Squamous cell lung cancer

Interventions

CBDCA AUC 3 (day 1)+ Amurubicin 35mg/m2 (day 1,2) q 2 weeks, 6-8 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histology/cytology-proven squamous cell lung cancer 2)Age<75 3)Stage IIIB, IV 4)Chemotherapy na&iuml;ve patients 5)Performance status(ECOG): 0-1 6)Adequate organ function 7)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Serious infections 2)Serious clinical problems 3)Interstitial pneumonia/lung fibrosis on chest CT 4)Active concomitant malignancy 5)Symptomatic brain metastasis 6)Massive pericardial, pleural effusion, ascites 7)Previous drug allergy 8)Those judged to be not suitable by the attending physician

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Safety Progression free survival Over all survival	—

Countries

Japan

Contacts

Public ContactMasao Ichiki

National Hospital Organization Kyushu Medical Center Department of Respiratory Medicine

ichiki@kyumed.jp092-852-0700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026